Krazati
Amgen's Lumakras Combo Scores High Response Rate in First-Line KRAS-Mutant Colorectal Cancer
Premium
Researchers reported at the ESMO Congress that 78 percent of patients responded to front-line treatment with Lumakras, Vectibix, and chemo.
Experts noted, however, there is insufficient evidence to determine which commercially available KRAS G12C inhibitor is the best treatment for brain metastases.
BMS Receives FDA Letter for Misleading Claims About Krazati's Efficacy in Promotional Material
The agency said BMS misrepresented the drug's efficacy data from the KRYSTAL-1 trial on its healthcare provider website.
Sales of the CAR T-cell therapy continue to grow helped by BMS's expansion of its cell manufacturing facilities.
FDA Approves BMS's Krazati With Cetuximab for KRAS G12C-Mutated Colorectal Cancer
BMS had submitted an application with the FDA earlier this year for approval of the drug with Erbitux for this patient population.
Apr 25, 2024